Development and standardization of multiplexed antibody microarrays for use in quantitative proteomics Public Deposited

Downloadable Content

Download PDF
Creator
  • Tchernev, VT
    • Other Affiliation: Molecular Staging Inc., 300 George St., New Haven, CT 06511 USA
  • Grimwade, B
    • Other Affiliation: Molecular Staging Inc., 300 George St., New Haven, CT 06511 USA
  • Kingsmore, SF
    • Other Affiliation: Molecular Staging Inc., 300 George St., New Haven, CT 06511 USA; National Center for Genome Resources, 2935 Rodeo Park Drive East, Santa Fe, NM 87505 USA
  • Shao, W
    • Other Affiliation: Molecular Staging Inc., 300 George St., New Haven, CT 06511 USA
  • Christiansen, J
    • Other Affiliation: Molecular Staging Inc., 300 George St., New Haven, CT 06511 USA
  • Patel, Dhavalkumar D
    • Affiliation: School of Medicine, Thurston Arthritis Research Center, Department of Medicine
  • Mullenix, M
    • Other Affiliation: Molecular Staging Inc., 300 George St., New Haven, CT 06511 USA
  • Lejnine, S
    • Other Affiliation: Molecular Staging Inc., 300 George St., New Haven, CT 06511 USA
  • Perlee, LT
    • Other Affiliation: Molecular Staging Inc., 300 George St., New Haven, CT 06511 USA
  • Sorette, M
    • Other Affiliation: Molecular Staging Inc., 300 George St., New Haven, CT 06511 USA
  • Dondero, R
    • Other Affiliation: Molecular Staging Inc., 300 George St., New Haven, CT 06511 USA
Abstract
  • Abstract Background Quantitative proteomics is an emerging field that encompasses multiplexed measurement of many known proteins in groups of experimental samples in order to identify differences between groups. Antibody arrays are a novel technology that is increasingly being used for quantitative proteomics studies due to highly multiplexed content, scalability, matrix flexibility and economy of sample consumption. Key applications of antibody arrays in quantitative proteomics studies are identification of novel diagnostic assays, biomarker discovery in trials of new drugs, and validation of qualitative proteomics discoveries. These applications require performance benchmarking, standardization and specification. Results Six dual-antibody, sandwich immunoassay arrays that measure 170 serum or plasma proteins were developed and experimental procedures refined in more than thirty quantitative proteomics studies. This report provides detailed information and specification for manufacture, qualification, assay automation, performance, assay validation and data processing for antibody arrays in large scale quantitative proteomics studies. Conclusion The present report describes development of first generation standards for antibody arrays in quantitative proteomics. Specifically, it describes the requirements of a comprehensive validation program to identify and minimize antibody cross reaction under highly multiplexed conditions; provides the rationale for the application of standardized statistical approaches to manage the data output of highly replicated assays; defines design requirements for controls to normalize sample replicate measurements; emphasizes the importance of stringent quality control testing of reagents and antibody microarrays; recommends the use of real-time monitors to evaluate sensitivity, dynamic range and platform precision; and presents survey procedures to reveal the significance of biomarker findings.
Date of publication
Identifier
  • doi:10.1186/1477-5956-2-9
  • 15598355
Resource type
  • Article
Rights statement
  • In Copyright
Rights holder
  • LT Perlee et al.; licensee BioMed Central Ltd.
License
Journal title
  • Proteome Science
Journal volume
  • 2
Journal issue
  • 1
Page start
  • 9
Language
  • English
Is the article or chapter peer-reviewed?
  • Yes
ISSN
  • 1477-5956
Bibliographic citation
  • Proteome Science. 2004 Dec 15;2(1):9
Access
  • Open Access
Publisher
  • BioMed Central Ltd
Parents:

This work has no parents.

Items